TP53 and B-cell chronic lymphocytic leukemia: Therefore, further studies with larger cohorts, including more cases with cth and preserved TP53, are needed to better understand the role of this phenomenon in CLL pathogenesis and prognosis, particularly in patients treated with new therapeutic agents, to better elucidate the potential of cth as a predictive marker.